Investigational drug · Phase 2
Evorpacept
Also called: ALX148
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
14
Any phase or sponsor naming "Evorpacept"
First trial start
2021
Jan 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Evorpacept", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer, Metastatic
- Plasma Cell Myeloma Refractory
- HER2-expressing Cancers
Approved drugs for the same conditions: Breast cancer · Head and neck cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Evorpacept" as an intervention, largest first.
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT05868226 · 280 participants (planned) · Start Feb 15, 2023 · Primary completion Dec 30, 2030
Drug: ALX148; Fam-Trastuzumab Deruxtecan-Nxki and 3 more · For: HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer and 29 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Aurora, Colorado · 10 sites in all
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
- Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)Pivotal-lookingActive, not recruiting
ALX Oncology Inc.Industry
NCT04675294 · 189 participants · Start Apr 2, 2021 · Primary completion Mar 3, 2025
Drug: evorpacept; pembrolizumab · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma
Sites: Irvine, California; La Jolla, California; Tampa, Florida · 53 sites in all
- A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)Completed
ALX Oncology Inc.Industry
NCT03013218 · 174 participants · Start Feb 3, 2017 · Primary completion Feb 1, 2022
Drug: Evorpacept (ALX148); Pembrolizumab and 4 more · For: Metastatic Cancer; Solid Tumor; Advanced Cancer and 1 more
Sites: Denver, Colorado; New Haven, Connecticut; Boston, Massachusetts · 10 sites in all
- Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Pivotal-lookingActive, not recruiting
ALX Oncology Inc.Industry
NCT04675333 · 172 participants · Start May 10, 2021 · Primary completion Mar 3, 2025
Drug: evorpacept; pembrolizumab and 1 more · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma
Sites: Irvine, California; La Jolla, California; Los Angeles, California · 44 sites in all
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Pivotal-lookingCompleted
ALX Oncology Inc.Industry
NCT05002127 · 127 participants · Start Jan 15, 2022 · Primary completion May 24, 2024
Drug: Evorpacept (ALX148); Trastuzumab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Anaheim, California; Los Angeles, California; Nashville, Tennessee · 83 sites in all
ALX Oncology Inc.Industry
NCT07007559 · 120 participants (planned) · Start Dec 10, 2025 · Primary completion Dec 2027
Drug: Evorpacept (ALX148); Trastuzumab and 5 more · For: Breast Cancer, Metastatic
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 61 sites in all
- A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)Terminated
ALX Oncology Inc.Industry
NCT04417517 · 65 participants · Start Oct 2, 2020 · Primary completion Jan 17, 2025
Drug: evorpacept; azacitidine · For: Higher Risk Myelodysplastic Syndromes
Sites: Los Angeles, California; Chicago, Illinois; Indianapolis, Indiana · 19 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05027139 · 52 participants · Start Sep 15, 2021 · Primary completion Aug 29, 2025
Drug: Zanidatamab; Evorpacept · For: HER2-expressing Cancers
Sites: La Jolla, California; Los Angeles, California; Orange, California · 11 sites in all
ALX Oncology Inc.Industry
NCT05524545 · 36 participants · Start Nov 2, 2022 · Primary completion Jun 27, 2025
Drug: Evorpacept; Enfortumab Vedotin · For: Bladder Cancer; Urothelial Carcinoma
Sites: Tampa, Florida; Boston, Massachusetts; New York, New York · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.
Abdelaziz AM, Shokr MM · Biochem Pharmacol 2026
- Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.
Shitara K, Wainberg Z, Tabernero J, et al. · Nat Med 2026
- Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma.
Hunzeker Z, de la Rosa FJ, Tyshevich A, et al. · Br J Haematol 2026
- Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.
Lee KW, Elimova E, Oh DY, et al. · Clin Cancer Res 2026
- Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.
Lentz RW, Lang J, Pitts TM, et al. · Cancer Res Commun 2025
- HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors.
Wang JT, Tseng CL, Teng HF, et al. · J Hematol Oncol 2025
Also in development for Head and Neck Cancer
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Buparlisib & PaclitaxelAN2025Phase 31 trial
Adlai Nortye Biopharma Co., Ltd. · Head and Neck Cancer
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- INCAGN02385Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- INCAGN02390Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- MCLA-129Phase 23 trials
Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer
- Carboplatin AUC-5Phase 22 trials
Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.